Full notification file
Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) with low blast counts failing to achieve an IWG defined response following azacitidine therapy.
Proposed period of release:
30/04/2015 to 31/12/2017
Name of the Institute(s) or Company(ies)
Cell Therapy Catapult, ;
3. Is the same GMO release planned elsewhere in the Community?
Belgium; France; United Kingdom;
Has the same GMO been notified elsewhere by the same notifier?
GMO is a:
Identity of the GMO:
Identity of the GMO (genus and species)
Species: Homo Sapiens
Information relating to the recipient or parental organisms from wich the GMO is derived
Myeloproliferative sarcoma virus
European Commission administrative information
Consent given by the Member State Competent Authority: